EXPLORING THE POTENTIAL BUDGET IMPACT OF EMICIZUMAB FOR HEMOPHILIA A WITH INHIBITOR IN ITALY

被引：0
|
作者：
Cortesi, P. A. [1 ]
D'Angiolella, L. S. [1 ]
Ferrario, M. [2 ]
Cesana, G. [1 ]
Mantovani, L. G. [1 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Roche SpA, Monza, Italy
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2619
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY42
引用
收藏
页码：S442 / S443
页数：3
相关论文
共 50 条
  • [1] EXPLORING THE POTENTIAL COST-EFFECTIVENESS OF EMICIZUMAB FOR HEMOPHILIA A WITH INHIBITOR IN ITALY
    D'Angiolella, L. S.
    Cortesi, P. A.
    Ferrario, M.
    Cesana, G.
    Mantovani, L. G.
    [J]. VALUE IN HEALTH, 2018, 21 : S452 - S452
  • [2] BUDGET IMPACT ANALYSIS OF RFVIII THERAPIES AND EMICIZUMAB FOR MANAGEMENT OF SEVERE HEMOPHILIA A
    Sun, S.
    Fan, T.
    Epstein, J.
    Ito, D.
    Xuan, D.
    [J]. VALUE IN HEALTH, 2019, 22 : S338 - S338
  • [3] Budget Impact of Emicizumab for Routine Prophylaxis of Bleeding Episodes in Patients With Hemophilia A With Inhibitors
    Watanabe, Alexandre Hikiji
    Lee, Shaun Wen Huey
    Chai-Adisaksopha, Chatree
    Lim, Ming Y.
    Chaiyakunapruk, Nathorn
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 7 - 13
  • [4] Usefulness of Emicizumab in Hemophilia Patients with Inhibitor
    Naga, Chiai
    Umezawa, Youtarou
    Mori, Mika
    Matsuoka, Akina
    Ashikaga, Tomoko
    Oyama, Ryo
    Keino, Dai
    Yamashita, Atsuki
    Mori, Tetsuya
    Taki, Masashi
    [J]. PEDIATRIC BLOOD & CANCER, 2018, 65 : S68 - S68
  • [5] Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor
    Kharel, Zeni
    Pruthi, Rajiv K.
    Kouides, Peter
    Reid, Robin
    [J]. HAEMOPHILIA, 2024, 30 (03) : 868 - 871
  • [6] Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance
    Young, Guy
    [J]. BLOOD ADVANCES, 2018, 2 (20) : 2780 - 2782
  • [7] Decrease in in vivo coagulant potential of emicizumab in a patient with hemophilia A and inhibitor complicated with infectious mononucleosis
    Furukawa, Shoko
    Ogiwara, Kenichi
    Yada, Koji
    Takeyama, Masahiro
    Niino, Tomomi
    Shima, Midori
    Keiji, Nogami
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2023, 34 (02) : 122 - 128
  • [8] Experience and Problems of Using Emicizumab in Hemophilia A Patients With Inhibitor
    Nagae, Chiai
    Mori, Mika
    Umezawa, Yotaro
    Sudo, Akina
    Tomoko, Ashikaga
    Oyama, Ryo
    Yamashita, Atsuki
    Mori, Tetsuya
    Taki, Masashi
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 : S71 - S71
  • [9] BUDGET IMPACT ANALYSIS OF THE USE OF EMICIZUMAB IN PROPHYLAXIS FOR SEVERE HEMOPHILIA A AND INHIBITORS IN THE PEDIATRIC COPULATION OF THE DOMINICAN REPUBLIC
    Munoz, A.
    Bustamante, A.
    Blanco, J.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S135 - S136
  • [10] Transplacental Transfer of Emicizumab: Experience with Emicizumab in a Pregnant Female with Severe Hemophilia. and an Inhibitor
    Kharel, Zeni
    Pruthi, Rajiv K.
    Kouides, Peter A.
    Reid, Robin
    [J]. BLOOD, 2023, 142
12345